Efficacy of up-front 5-fluorouracil - Epidoxorubicin - cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients

E. Van Der Wall, E. J T Rutgers, M. J. Holtkamp, J. W. Baars, J. H. Schornagel, J. L. Peterse, J. H. Beijnen, S. Rodenhuis

Research output: Contribution to journalArticle

Abstract

The prognosis of patients with stage IIIB breast carcinoma with tumour spread to the apical axillary lymph nodes has hardly improved despite adequate locoregional control and the introduction of systemic adjuvant therapy. A combined modality regimen that includes anthracyclin-based chemotherapy, high-dose chemotherapy with peripheral stem cell support and radiation and hormonal therapy is currently under investigation in this subset of patients. The present study aims to document the efficacy and feasibility of dose-intensive epidoxorubicin in combination with a standard dose of 5-fluorouracil and cyclophosphamide as up-front chemotherapy in this setting. A preoperative chemotherapy regimen consisting of three courses of 5-fluorouracil 500 mg m 2, epidoxorubicin 120 mg m 2 and cyclophosphamide 500 mg m 2 (FE120C) was administered at 21 day intervals without haematopoietic growth factors to 70 patients with apex node-positive disease. All patients were below 60 years of age and had not had prior chemotherapy or radiotherapy. Sixty-six patients were evaluable for clinical response and histopathological examination could be performed in 62 of these. Thirteen patients achieved a clinical complete response (20%). Of these patients, microscopic examination of the mastectomy specimen revealed absence of malignant cells in two and exclusively ductal carcinoma in situ (DCIS) in another two patients. In addition, of the 46 patients (70%) with a clinical partial response, at pathological examination one patient had sclerosis only and four had DCIS. This results in a pathological complete response in three (5%) of all patients and absence of invasive carcinoma in 10%. None of the patients progressed during chemotherapy. The major toxicity was moderate bone marrow suppression with a median white blood count (WBC) nadir of 1800 μl 1 (range 500-4900). Other toxicities were mild. The full planned dose could be given without delays in 66 of 70 patients. FE120C is well tolerated and is highly effective as up-front chemotherapy in relatively young patients with high-risk breast cancer, with a 90% (CI 74 98%) clinical objective response rate.

Original languageEnglish (US)
Pages (from-to)1080-1085
Number of pages6
JournalBritish Journal of Cancer
Volume73
Issue number9
StatePublished - 1996
Externally publishedYes

Fingerprint

Fluorouracil
Cyclophosphamide
Breast Neoplasms
Drug Therapy
Carcinoma, Intraductal, Noninfiltrating
Radiotherapy
Mastectomy
Sclerosis
Intercellular Signaling Peptides and Proteins
Lymph Nodes
Bone Marrow

Keywords

  • Breast cancer
  • High-dose epidoxorubicin
  • Up-front chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Van Der Wall, E., Rutgers, E. J. T., Holtkamp, M. J., Baars, J. W., Schornagel, J. H., Peterse, J. L., ... Rodenhuis, S. (1996). Efficacy of up-front 5-fluorouracil - Epidoxorubicin - cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients. British Journal of Cancer, 73(9), 1080-1085.

Efficacy of up-front 5-fluorouracil - Epidoxorubicin - cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients. / Van Der Wall, E.; Rutgers, E. J T; Holtkamp, M. J.; Baars, J. W.; Schornagel, J. H.; Peterse, J. L.; Beijnen, J. H.; Rodenhuis, S.

In: British Journal of Cancer, Vol. 73, No. 9, 1996, p. 1080-1085.

Research output: Contribution to journalArticle

Van Der Wall, E, Rutgers, EJT, Holtkamp, MJ, Baars, JW, Schornagel, JH, Peterse, JL, Beijnen, JH & Rodenhuis, S 1996, 'Efficacy of up-front 5-fluorouracil - Epidoxorubicin - cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients', British Journal of Cancer, vol. 73, no. 9, pp. 1080-1085.
Van Der Wall, E. ; Rutgers, E. J T ; Holtkamp, M. J. ; Baars, J. W. ; Schornagel, J. H. ; Peterse, J. L. ; Beijnen, J. H. ; Rodenhuis, S. / Efficacy of up-front 5-fluorouracil - Epidoxorubicin - cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients. In: British Journal of Cancer. 1996 ; Vol. 73, No. 9. pp. 1080-1085.
@article{1b03b4fd31c349449314bef5c2e8447b,
title = "Efficacy of up-front 5-fluorouracil - Epidoxorubicin - cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients",
abstract = "The prognosis of patients with stage IIIB breast carcinoma with tumour spread to the apical axillary lymph nodes has hardly improved despite adequate locoregional control and the introduction of systemic adjuvant therapy. A combined modality regimen that includes anthracyclin-based chemotherapy, high-dose chemotherapy with peripheral stem cell support and radiation and hormonal therapy is currently under investigation in this subset of patients. The present study aims to document the efficacy and feasibility of dose-intensive epidoxorubicin in combination with a standard dose of 5-fluorouracil and cyclophosphamide as up-front chemotherapy in this setting. A preoperative chemotherapy regimen consisting of three courses of 5-fluorouracil 500 mg m 2, epidoxorubicin 120 mg m 2 and cyclophosphamide 500 mg m 2 (FE120C) was administered at 21 day intervals without haematopoietic growth factors to 70 patients with apex node-positive disease. All patients were below 60 years of age and had not had prior chemotherapy or radiotherapy. Sixty-six patients were evaluable for clinical response and histopathological examination could be performed in 62 of these. Thirteen patients achieved a clinical complete response (20{\%}). Of these patients, microscopic examination of the mastectomy specimen revealed absence of malignant cells in two and exclusively ductal carcinoma in situ (DCIS) in another two patients. In addition, of the 46 patients (70{\%}) with a clinical partial response, at pathological examination one patient had sclerosis only and four had DCIS. This results in a pathological complete response in three (5{\%}) of all patients and absence of invasive carcinoma in 10{\%}. None of the patients progressed during chemotherapy. The major toxicity was moderate bone marrow suppression with a median white blood count (WBC) nadir of 1800 μl 1 (range 500-4900). Other toxicities were mild. The full planned dose could be given without delays in 66 of 70 patients. FE120C is well tolerated and is highly effective as up-front chemotherapy in relatively young patients with high-risk breast cancer, with a 90{\%} (CI 74 98{\%}) clinical objective response rate.",
keywords = "Breast cancer, High-dose epidoxorubicin, Up-front chemotherapy",
author = "{Van Der Wall}, E. and Rutgers, {E. J T} and Holtkamp, {M. J.} and Baars, {J. W.} and Schornagel, {J. H.} and Peterse, {J. L.} and Beijnen, {J. H.} and S. Rodenhuis",
year = "1996",
language = "English (US)",
volume = "73",
pages = "1080--1085",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Efficacy of up-front 5-fluorouracil - Epidoxorubicin - cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients

AU - Van Der Wall, E.

AU - Rutgers, E. J T

AU - Holtkamp, M. J.

AU - Baars, J. W.

AU - Schornagel, J. H.

AU - Peterse, J. L.

AU - Beijnen, J. H.

AU - Rodenhuis, S.

PY - 1996

Y1 - 1996

N2 - The prognosis of patients with stage IIIB breast carcinoma with tumour spread to the apical axillary lymph nodes has hardly improved despite adequate locoregional control and the introduction of systemic adjuvant therapy. A combined modality regimen that includes anthracyclin-based chemotherapy, high-dose chemotherapy with peripheral stem cell support and radiation and hormonal therapy is currently under investigation in this subset of patients. The present study aims to document the efficacy and feasibility of dose-intensive epidoxorubicin in combination with a standard dose of 5-fluorouracil and cyclophosphamide as up-front chemotherapy in this setting. A preoperative chemotherapy regimen consisting of three courses of 5-fluorouracil 500 mg m 2, epidoxorubicin 120 mg m 2 and cyclophosphamide 500 mg m 2 (FE120C) was administered at 21 day intervals without haematopoietic growth factors to 70 patients with apex node-positive disease. All patients were below 60 years of age and had not had prior chemotherapy or radiotherapy. Sixty-six patients were evaluable for clinical response and histopathological examination could be performed in 62 of these. Thirteen patients achieved a clinical complete response (20%). Of these patients, microscopic examination of the mastectomy specimen revealed absence of malignant cells in two and exclusively ductal carcinoma in situ (DCIS) in another two patients. In addition, of the 46 patients (70%) with a clinical partial response, at pathological examination one patient had sclerosis only and four had DCIS. This results in a pathological complete response in three (5%) of all patients and absence of invasive carcinoma in 10%. None of the patients progressed during chemotherapy. The major toxicity was moderate bone marrow suppression with a median white blood count (WBC) nadir of 1800 μl 1 (range 500-4900). Other toxicities were mild. The full planned dose could be given without delays in 66 of 70 patients. FE120C is well tolerated and is highly effective as up-front chemotherapy in relatively young patients with high-risk breast cancer, with a 90% (CI 74 98%) clinical objective response rate.

AB - The prognosis of patients with stage IIIB breast carcinoma with tumour spread to the apical axillary lymph nodes has hardly improved despite adequate locoregional control and the introduction of systemic adjuvant therapy. A combined modality regimen that includes anthracyclin-based chemotherapy, high-dose chemotherapy with peripheral stem cell support and radiation and hormonal therapy is currently under investigation in this subset of patients. The present study aims to document the efficacy and feasibility of dose-intensive epidoxorubicin in combination with a standard dose of 5-fluorouracil and cyclophosphamide as up-front chemotherapy in this setting. A preoperative chemotherapy regimen consisting of three courses of 5-fluorouracil 500 mg m 2, epidoxorubicin 120 mg m 2 and cyclophosphamide 500 mg m 2 (FE120C) was administered at 21 day intervals without haematopoietic growth factors to 70 patients with apex node-positive disease. All patients were below 60 years of age and had not had prior chemotherapy or radiotherapy. Sixty-six patients were evaluable for clinical response and histopathological examination could be performed in 62 of these. Thirteen patients achieved a clinical complete response (20%). Of these patients, microscopic examination of the mastectomy specimen revealed absence of malignant cells in two and exclusively ductal carcinoma in situ (DCIS) in another two patients. In addition, of the 46 patients (70%) with a clinical partial response, at pathological examination one patient had sclerosis only and four had DCIS. This results in a pathological complete response in three (5%) of all patients and absence of invasive carcinoma in 10%. None of the patients progressed during chemotherapy. The major toxicity was moderate bone marrow suppression with a median white blood count (WBC) nadir of 1800 μl 1 (range 500-4900). Other toxicities were mild. The full planned dose could be given without delays in 66 of 70 patients. FE120C is well tolerated and is highly effective as up-front chemotherapy in relatively young patients with high-risk breast cancer, with a 90% (CI 74 98%) clinical objective response rate.

KW - Breast cancer

KW - High-dose epidoxorubicin

KW - Up-front chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0029972405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029972405&partnerID=8YFLogxK

M3 - Article

C2 - 8624267

AN - SCOPUS:0029972405

VL - 73

SP - 1080

EP - 1085

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 9

ER -